The immune system and electroconvulsive therapy for depression

Journal of ECT

Volumn 30, Issue 2, 2014, Pages 132-137

  Guloksuz, Sinan ^a,b   Rutten, Bart P F ^a   Arts, Baer ^a   Van Os, Jim ^a,c   Kenis, Gunter ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytokine; Depression; ECT; Immunology; Inflammation; Mechanism

Indexed keywords

CD38 ANTIGEN; EOTAXIN 3; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

CELL ACTIVITY; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DEPRESSION; DOWN REGULATION; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FRONTAL LOBE; HEREDITY; HUMAN; IMMUNE ACTIVATION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; INFLAMMATION; MAJOR DEPRESSION; MENTAL PERFORMANCE; MENTAL STRESS; NATURAL KILLER CELL; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; WORKING MEMORY; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES;

DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMANS; IMMUNE SYSTEM;

EID: 84901639399     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000127     Document Type: Review

References (53)

1. The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet. 2003;361:799-808.
2. McCall WV, Andrade C, Sienaert P. Searching for the mechanism(s) of ECT's therapeutic effect. J ECT. 2014;30:87-89.
3. Lanzenberger R. Neurotransmitters and ECT. J ECT. 2014;30:116-121.
4. Haskett RF. Neuroendocrine hypotheses, including pituitary-adrenal axis. J ECT. 2014;30:107-110.
5. Farzan F, Boutros NN, Blumberger DM, et al. What does the electroencephalogram tell us about the mechanisms of action of ECT in major depressive disorders? J ECT. 2014;30:98-106.
6. Bolwig TG. Imaging the brain during/after ECT: A look inside the mechanism of action. J ECT. 2014;30:143-152.
7. Bolwig TG. How does electroconvulsive therapy work? Theories on its mechanism. Can J Psychiatry. 2011;56:13-18.
8. Fink M. Should the dexamethasone suppression test be resurrected? Acta Psychiatr Scand. 2005;112:245-249. (Pubitemid 41382730)
9. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol. 2013;8:900-920.
10. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24-31. (Pubitemid 43083561)
11. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun. 2001;15:199-226. (Pubitemid 33070955)
12. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35:298-306.
13. Wium-Andersen MK, Orsted DD, Nielsen SF, et al. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry. 2013;70:176-184.
14. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med. 2009;71:171-186.
15. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67: 446-457.
16. Wichers MC, Kenis G, Koek GH, et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res. 2007;62:207-214. (Pubitemid 46161588)
17. Kenis G, Prickaerts J, van Os J, et al. Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 2011;14:247-253.
18. Bufalino C, Hepgul N, Aguglia E, et al. The role of immune genes in the association between depression and inflammation: A review of recent clinical studies. Brain Behav Immun. 2013;31:31-47.
19. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
20. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37:137-162.
21. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279:1375-1385.
22. Zunszain PA, Anacker C, Cattaneo A, et al. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:722-729.
23. Miller AH, Haroon E, Raison CL, et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30:297-306.
24. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5:401-412. (Pubitemid 35470359)
25. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotonin-noradrenalin antidepressants on cytokine production: A review of the current literature. Int J Immunopathol Pharmacol. 2010;23:417-422.
26. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology. 2011;36:2452-2459.
27. Hiles SA, Baker AL, de Malmanche T, et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: A meta-analysis. Psychol Med. 2012;42:2015-2026.
28. Vogelzangs N, Duivis HE, Beekman AT, et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry. 2012;2:e79.
29. Raison CL, Miller AH. Do cytokines really sing the blues? Cerebrum. 2013;2013:10.
30. Vogelzangs N, Beekman AT, van Reedt Dortland AK, et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology. 2014. doi: 10.1038/npp.2014.9.
31. Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline "predictors" and longitudinal "targets". Neuropsychopharmacology. 2013; 38: 377-385.
32. Guloksuz S, Wichers M, Kenis G, et al. Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability. PLoS One. 2013;8:e60435.
33. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry. 2013;70:31-41.
34. Albrecht J, Helderman JH, Schlesser MA, et al. A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Res. 1985;15:185-193. (Pubitemid 15042330)
35. Kronfol Z, Lemay L, Madhavan N, et al. Electroconvulsive therapy increases plasma levels of interleukin-6. Ann N Y Acad Sci. 1990;594:463-465. (Pubitemid 20298267)
36. Fischler B, Bocken R, Schneider I, et al. Immune changes induced by electroconvulsive therapy (ECT). Ann N Y Acad Sci. 1992;650: 326-330.
37. Zachrisson OC, Balldin J, Ekman R, et al. No evident neuronal damage after electroconvulsive therapy. Psychiatry Res. 2000;96:157-165.
38. Agelink MW, Andrich J, Postert T, et al. Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. J Neurol Neurosurg Psychiatry. 2001;71:394-396. (Pubitemid 32772541)
39. Kronfol Z, Nair MP, Weinberg V, et al. Acute effects of electroconvulsive therapy on lymphocyte natural killer cell activity in patients with major depression. J Affect Disord. 2002;71:211-215.
40. Hestad KA, Tonseth S, Stoen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT. 2003;19:183-188. (Pubitemid 38018294)
41. Arts B, Peters M, Ponds R, et al. S100 and impact of ECT on depression and cognition. J ECT. 2006;22:206-212. (Pubitemid 44379377)
42. Lehtimaki K, Keranen T, Huuhka M, et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT. 2008;24:88-91. (Pubitemid 351498648)
43. Fluitman SB, Heijnen CJ, Denys DA, et al. Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord. 2011;131:388-392.
44. Rotter A, Biermann T, Stark C, et al. Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. J ECT. 2013;29:162-169.
45. Schroeter ML, Sacher J, Steiner J, et al. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets. 2013;14:1237-1248.
46. Jinno S, Kosaka T. Reduction of Iba1-expressing microglial process density in the hippocampus following electroconvulsive shock. Exp Neurol. 2008;212:440-447.
47. Roman A, Nawrat D, Nalepa I. Chronic treatment with electroconvulsive shock may modulate the immune function of macrophages. J ECT. 2008;24:260-267.
48. Roman A, Nalepa I. Effect of repeated administration of paroxetine and electroconvulsive shock on the proliferative response of lymphocytes and the synthesis of nitric oxide by macrophages in rats. J ECT. 2005;21:111-117. (Pubitemid 40800038)
49. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res. 1999;33:407-418. (Pubitemid 29392689)
50. Wang N, Wang XH, Lu J, et al. The effect of repeated etomidate anesthesia on adrenocortical function during a course of electroconvulsive therapy. J ECT. 2011;27:281-285.
51. Mitchell P, Smythe G, Torda T. Effect of the anesthetic agent propofol on hormonal responses to ECT. Biol Psychiatry. 1990;28:315-324. (Pubitemid 20253248)
52. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33:355-366.
53. McClintock SM, Choi J, Deng Z-D, et al. Multifactorial Determinants of the Neurocognitive Effects of Electroconvulsive Therapy. J ECT. 2014;30:165-176.